Amgen pushes back against regulators seeking to pull a key drug, while Pfizer faces investor skepticism over its obesity candidate. Meanwhile, Merck details an ambitious plan to offset the looming patent cliff of its blockbuster Keytruda and reach $70 billion in annual sales.
Early clinical results for Pfizer's acquired obesity drug PF-3944 show it may fall short of the high bar set by market leaders, raising questions about its competitive edge in the lucrative weight-loss market.
Truist Securities has raised its price target on Jazz Pharmaceuticals (JAZZ) to $230, citing 'practice-changing' results from the HERIZON-GEA trial for its drug Zepzelca in gastroesophageal adenocarcinoma. The firm maintains a Buy rating, anticipating strong commercial adoption and potential guideline inclusion.
Analysts at Leerink Partners have raised their price target for Bristol-Myers Squibb (BMY), highlighting a series of pivotal clinical trial results expected in 2025. The firm sees significant upside potential as the market currently undervalues the company's robust pipeline, despite near-term earnings adjustments.
New late-breaking data for Nektar Therapeutics' lead drug candidate, rezpegaldesleukin, suggests systemic anti-inflammatory benefits in patients with comorbid asthma, potentially expanding its market reach and strengthening the investment case for the biopharma firm.
Erasca Inc. (ERAS) sees its price target raised from $5 to $12 by Guggenheim, following promising clinical data for its lead oncology candidates and updated financial models. The move comes amid a series of positive analyst revisions for the clinical-stage biopharma firm.
Bank of America has raised its price target for clinical-stage biopharma firm Xencor (XNCR), highlighting a cautiously improving landscape for the sector driven by data catalysts, M&A, and capital access.
Equifax's stock has plummeted 32% over the past year, significantly underperforming the broader market. As investors reassess the credit reporting sector, a deep dive into valuation metrics reveals a complex picture: while a cash flow model suggests a steep discount, traditional price-to-earnings ratios tell a more cautious story.
Bloom Energy's stock has surged over 70% this year, fueled by multi-billion dollar agreements with American Electric Power and Brookfield. Analysts now question whether the solid oxide fuel cell maker's premium valuation is justified by its role in powering the AI boom.
A New York Fed analysis of consumer spending from 2023-2025 shows a stark and growing divide between college graduates and non-graduates, providing fresh evidence of a 'K-shaped' economic recovery where the educated continue to outpace others.
U.S. wheat futures edged lower in Wednesday's session, with all three major classes showing modest declines as traders await key export sales figures for market direction.
Lean hog futures presented a mixed picture on Wednesday, with prices fluctuating across contracts as the USDA reported a slight increase in the national base price. Market analysts are weighing recent slaughter figures against seasonal demand trends.
Elon Musk consolidates his space and AI ventures, positioning SpaceX's Starship rocket as the cornerstone for an ambitious vision of space-based computing infrastructure.
A sharp reversal in institutional ETF flows, weakening U.S. demand, and tightening market liquidity are signaling a potential regime shift for Bitcoin, with analysts warning of further downside risk.
Buoyed by record orders and a surging backlog, Johnson Controls International plc kicks off fiscal 2026 with robust growth, margin expansion, and heightened confidence, driven largely by its pivotal role in cooling the AI revolution.
As investors look beyond the index's recent strong run, a century-old pattern linked to U.S. midterm elections points to potential volatility ahead—and possible gains thereafter.
With AI chip power demands soaring, Vertiv Holdings Co's advanced cooling solutions are emerging as a critical bottleneck—and a strategic investment. Its deep partnership with Nvidia provides a key competitive edge in a market where reliability trumps cost.
Lean hog futures posted solid gains to start the week, buoyed by a stronger cash market and firming pork cutout values. Traders are positioning cautiously ahead of Wednesday's USDA Cold Storage report, which could dictate near-term price direction.
Wheat markets opened lower across the board Wednesday, extending a choppy trading pattern as traders weigh steady EU export volumes against domestic weather forecasts and technical pressure.
U.S. corn prices edged lower in Wednesday's pre-market session, giving back a portion of the previous day's gains. Traders are weighing fresh Treasury guidance on biofuel tax credits against expectations for softer ethanol output and ongoing global demand.
